<DOC>
	<DOCNO>NCT00345670</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , dose-escalation , Phase 1 , multi-center study evaluate safety , tolerability , immunogenicity , viral shed MEDI-534 healthy child 1-9 year age seropositive respiratory syncytial virus ( RSV ) parainfluenza virus type 3 ( PIV3 ) screening .</brief_summary>
	<brief_title>Study Evaluate Safety MEDI-534 Vaccine Against Respiratory Syncytial Virus ( RSV ) Parainfluenza Virus Type 3 ( PIV3 ) Healthy Children</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , dose-escalation Phase 1 multi-center study evaluate safety , tolerability , immunogenicity , viral shed MEDI-534 healthy child 1-9 year age seropositive RSV PIV3 screen . MEDI-534 administered dosage level 10:4 TCID50 , 10:5 TCID50 , 10:6 TCID50 three cohort subject stagger , step-wise fashion . A single dose study vaccine ( MEDI-534 match volume vehicle placebo ) administer Study Day 0 nasal spray , one-half dose nostril . The target sample size 120 subject randomize 1:1 ( MEDI-534 placebo ) , 40 subject three cohort . Randomization stratify site . This study enroll RSV season multiple site United States Chile .</detailed_description>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<criteria>Male female age 1 9 year old In general good health Seropositive RSV ( enzymelinked immunosorbent assay [ ELISA ] titer &gt; 12 U/ml ) PIV3 ( hemagglutinationinhibition [ HAI ] titer &gt; 1:8 ) Subject 's parent/legal representative available telephone Written inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization ( applicable ) obtain subject 's parent/legal representative Ability subject 's parent/legal representative understand comply requirement protocol judged investigator Ability complete followup period 6 month follow dosing require protocol Any fever and/or respiratory illness ( e.g. , cough sore throat ) within 7 day prior randomization Any drug therapy ( chronic ) within 7 day prior randomization expect receipt therapy protocolspecified blood collection 2835 day study vaccine dose Any current expect receipt systemic immunosuppressive agent include steroid ; child category receive study vaccine immunosuppressive agent include corticosteroid therapy discontinue less equal 30 day Receipt blood transfusion within 7 month prior randomization expect receipt 35 day study vaccine dose Receipt immunoglobulin product within 11 month prior randomization expect receipt 35 day study vaccine dose Receipt investigational drug within 60 day prior randomization expect receipt 180 day study vaccine dose Receipt live virus vaccine within 30 day prior randomization expect receipt protocolspecified blood collection 2835 day study vaccine dose Receipt inactivate ( i.e. , nonlive ) vaccine within 14 day prior randomization expect receipt protocolspecified blood collection 2835 day study vaccine dose History GuillainBarr√© syndrome Known suspect immunodeficiency , include HIV Known suspect acute chronic hepatitis infection Living home attend day care child less equal 24 month age Contact pregnant caregiver Household contact immunocompromised ; subject also avoid close contact immunocompromised individual least 30 day study vaccine dose History hypersensitivity kanamycin aminoglycoside antibiotic ( gentamicin , tobramycin , etc ) Previous medical history , evidence , chronic illness may compromise safety subject At screen follow laboratory test outside laboratory normal range : complete blood count ( CBC ) differential platelet count , AST , ALT , blood urea nitrogen ( BUN ) , creatinine , abnormal laboratory value screen panel , opinion principal investigator , consider clinically significant may potentially compromise safety subject conduct study History medically confirm diagnosis asthma , reactive airway disease , chronic obstructive pulmonary disease ( COPD ) Passive primary household smoke Family member household contact employee research center conduct study Any condition , opinion investigator , might interfere study vaccine evaluation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Lower respiratory tract illness</keyword>
	<keyword>RSV PIV3 infection</keyword>
</DOC>